Afdiex - Afdiex is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Afdiex has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Afdiex appears to be completely metabolized, likely in the liver. Although its metabolites exert a small hypoglycemic effect, their contribution to glyburide’s hypoglycemic effect is thought to be clinically unimportant. Afdiex metabolites are excreted in urine and feces in approximately equal proportions. The half-life of Afdiex appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m2.|
Indication: Indicated as an adjunct to diet to lower the blood glucose in patients with NIDDM whose hyperglycemia cannot be satisfactorily controlled by diet alone.
Afdiex, a second-generation sulfonylurea antidiabetic agent, lowers blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonyl-urea hypoglycemic drugs. The combination of glibenclamide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. In addition to its blood glucose lowering actions, Afdiex produces a mild diuresis by enhancement of renal free water clearance. Afdiex is twice as potent as the related second-generation agent glipizide.
Pharmaceutical active ingredients containing related brand and generic drugs, medications or other health care products:
Afdiex available forms, composition, doses:
- Tablets; Oral; Glyburide 2.5 mg
- Tablets; Oral; Glyburide 5 mg
Afdiex destination | category:
- Antidiabetic agents
Indications and usages, anatomical therapeutic chemical and diseases classification codes:
Pharmaceutical companies, researchers, developers, manufacturers, distributors and suppliers:
There is no reviews yet. Be the first to write one!